Quidel Corporation (NASDAQ:QDEL) CEO Douglas C. Bryant sold 12,000 shares of the firm’s stock in a transaction on Monday, October 30th. The stock was sold at an average price of $41.15, for a total value of $493,800.00. Following the completion of the transaction, the chief executive officer now directly owns 296,493 shares of the company’s stock, valued at $12,200,686.95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Quidel Corporation (NASDAQ:QDEL) last released its earnings results on Wednesday, November 1st. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.20. The company had revenue of $50.89 million for the quarter, compared to analyst estimates of $50.47 million. Quidel Corporation had a negative return on equity of 0.03% and a negative net margin of 0.03%. Quidel Corporation’s quarterly revenue was up 3.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.10 EPS.
COPYRIGHT VIOLATION WARNING: This article was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://sportsperspectives.com/2017/11/02/douglas-c-bryant-sells-12000-shares-of-quidel-corporation-qdel-stock-2.html.
A number of institutional investors have recently bought and sold shares of the business. Nationwide Fund Advisors raised its position in shares of Quidel Corporation by 5.0% during the third quarter. Nationwide Fund Advisors now owns 226,223 shares of the company’s stock worth $9,922,000 after acquiring an additional 10,869 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Quidel Corporation during the second quarter worth approximately $442,000. The Manufacturers Life Insurance Company grew its stake in Quidel Corporation by 1.5% during the second quarter. The Manufacturers Life Insurance Company now owns 21,831 shares of the company’s stock worth $593,000 after purchasing an additional 333 shares during the period. Arrowstreet Capital Limited Partnership acquired a new stake in Quidel Corporation during the second quarter worth approximately $2,620,000. Finally, C M Bidwell & Associates Ltd. acquired a new stake in Quidel Corporation during the second quarter worth approximately $364,000. Hedge funds and other institutional investors own 86.92% of the company’s stock.
Several research analysts recently commented on QDEL shares. TheStreet raised Quidel Corporation from a “c+” rating to a “b-” rating in a research report on Thursday, July 6th. Raymond James Financial, Inc. reaffirmed a “buy” rating and issued a $47.00 target price (up from $41.00) on shares of Quidel Corporation in a research report on Tuesday, September 19th. Canaccord Genuity raised Quidel Corporation from a “hold” rating to a “buy” rating in a research report on Tuesday, July 18th. Zacks Investment Research raised Quidel Corporation from a “hold” rating to a “buy” rating and set a $30.00 target price for the company in a research report on Tuesday, July 18th. Finally, BidaskClub cut Quidel Corporation from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 16th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $48.00.
Quidel Corporation Company Profile
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.
Receive News & Ratings for Quidel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel Corporation and related companies with MarketBeat.com's FREE daily email newsletter.